|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000941,
umls-concept:C0017431,
umls-concept:C0022877,
umls-concept:C0026766,
umls-concept:C0031238,
umls-concept:C0205147,
umls-concept:C1514811,
umls-concept:C1519941,
umls-concept:C1522240,
umls-concept:C1561577,
umls-concept:C1706462
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-12
|
|
pubmed:abstractText |
Although considerable effort has been put into the development and evaluation of new diagnostics for tuberculosis (TB) and multidrug-resistant TB (MDR-TB), little attention has thus far been paid to the technical aspects of initiating quality-assured routine service use. For implementation of the microscopic-observation drug susceptibility (MODS) methodology in the Peruvian reference laboratory network, a laboratory accreditation process was devised; MODS results from an expert reference laboratory (Universidad Peruana Cayetano Heredia [UPCH]) were used as the standard against which implementing laboratory MODS results were judged to ensure that, prior to use for patient care, implementing laboratories achieved the same high performance with MODS as previously demonstrated in the research laboratory.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-10699023,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-15472289,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-16704831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-16898366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-17035648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-17072458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-17251409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-17537937,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-18202343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-18284841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-19284561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-19329799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-19457256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20937190-843571
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1815-7920
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1475-80
|
|
pubmed:dateRevised |
2011-7-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20937190-Accreditation,
pubmed-meshheading:20937190-Antitubercular Agents,
pubmed-meshheading:20937190-Bacteriological Techniques,
pubmed-meshheading:20937190-Humans,
pubmed-meshheading:20937190-Isoniazid,
pubmed-meshheading:20937190-Laboratories,
pubmed-meshheading:20937190-Microbial Sensitivity Tests,
pubmed-meshheading:20937190-Mycobacterium,
pubmed-meshheading:20937190-Peru,
pubmed-meshheading:20937190-Quality Assurance, Health Care,
pubmed-meshheading:20937190-Reference Standards,
pubmed-meshheading:20937190-Rifampin,
pubmed-meshheading:20937190-Tuberculosis,
pubmed-meshheading:20937190-Tuberculosis, Multidrug-Resistant
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.
|
|
pubmed:affiliation |
Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Validation Studies
|
